#Germany #Berlin #Lutetium-177 #Eckert Ziegler #AtomVie

Eckert & Ziegler and AtomVie Global Radiopharma: A Strategic Collaboration

Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have announced a significant global supply agreement for Lutetium-177 chloride, a key product in the radiopharmaceutical sector. This partnership marks an important milestone in the field of nuclear medicine and therapeutic innovation.

Under this agreement, Eckert & Ziegler will supply its non-carrier added Lutetium-177 chloride (n.c.a. Lu-177), branded as Theralugand®, to support AtomVie’s contract development and manufacturing organization (CDMO) activities. The deal encompasses various stages of product development, reinforcing a commitment to harnessing Lutetium-177 for innovative radiopharmaceutical therapies.

Significance of the Agreement

This collaboration emphasizes reliability and adaptability in a rapidly evolving market. By providing Theralugand®, Eckert & Ziegler empowers AtomVie to develop the next generation of radiopharmaceuticals effectively. The flexibility inherent in the agreement allows both companies to accommodate the specific needs of their pharmaceutical partners, addressing a spectrum of regulatory conditions across global markets.

Dr. Harald Hasselmann, CEO of Eckert & Ziegler, expressed optimism about the collaboration, stating, "We are happy to support AtomVie in advancing global radiopharmaceutical development programs with Theralugand®. By supplying our high-quality radionuclides, we are making a significant contribution to the evolution of therapeutic approaches within nuclear medicine." This sentiment underscores the joint dedication to enhance medical treatment options for patients worldwide.

Bruno Paquin, the CEO of AtomVie, echoed these sentiments, highlighting the strategic nature of the partnership: "Partnering with Eckert & Ziegler is a significant step in ensuring that our global partners developing Lutetium-177 based radiopharmaceuticals have the support they need. Our upcoming facility is set to bolster our manufacturing capabilities, enabling us to provide reliable, high-quality services to our clients. We look forward to making strides in innovation and positively impacting patients' lives together with our partners."

About Eckert & Ziegler

Eckert & Ziegler SE stands as a leading specialist in isotope-related components tailored for nuclear medicine and radiation therapy. With a robust workforce exceeding 1,000 employees, the company provides a comprehensive portfolio of products and services spanning from initial developmental processes to comprehensive contract manufacturing and distribution solutions tailored for the radiopharmaceutical industry. Eckert & Ziegler’s shares are publicly traded under the ISIN DE0005659700 in the TecDAX index of Deutsche Börse, further establishing its industry prominence.

About AtomVie Global Radiopharma

Located in Hamilton, Ontario, AtomVie Global Radiopharma Inc. specializes as a contract development and manufacturing organization for Good Manufacturing Practice (GMP) compliant radiopharmaceuticals. The company combines scientific expertise with logistical capabilities to navigate the complexities of radiopharmaceutical development, ensuring clients can smoothly transition from clinical studies to commercial production. AtomVie’s commitment to excellence has earned it a reputation as a trusted partner, currently serving clients in over 25 countries globally.

Conclusion

The partnership between Eckert & Ziegler and AtomVie Global Radiopharma represents a forward-looking alliance poised to influence the future of radiopharmaceuticals significantly. By synergizing their strengths, both companies are set to redefine therapeutic approaches, ensuring better health outcomes for patients relying on advanced medical therapies. As these two pioneers in the industry continue to advance their collective vision, the implications for global health and innovation in nuclear medicine remain profoundly promising.